RPG Life Sciences plans analyst meet on September 22 at 10 am

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • RPG Life Sciences to host investor meet on September 22, 2026
  • Session part of Anand Rathi G-200 Summit in Mumbai
  • Group and one-on-one sessions planned for market participants
powered bylight_fuzz_icon
51191085

*this image is generated using AI for illustrative purposes only.

RPG Life Sciences will host an analyst and institutional investor meet on September 22, 2026. The session is part of the Anand Rathi G-200 Summit 2026, scheduled for 10:00 am onwards in Mumbai.

The company disclosed the engagement pursuant to Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Rajesh Shirambekar, Head-Legal & Company Secretary, signed the disclosure dated September 17, 2026.

Meeting Details

The event will be held in a physical format in Mumbai. RPG Life Sciences will conduct both group and one-on-one sessions with market participants during the summit.

Date Time Host/Event Venue/Mode Nature
September 22, 2026 10:00 am onwards Anand Rathi G-200 Summit 2026 Mumbai/Physical Group/One-on-one

Disclosures

The date is subject to change due to exigencies on the part of the company or the host. Any presentation made during the meet will align with the content available on the company and stock exchange websites.

Historical Stock Returns for RPG Life Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-3.29%-7.22%-2.98%+45.21%+19.92%+294.09%
Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

What specific strategic updates or financial guidance is RPG Life Sciences expected to unveil at the Anand Rathi G-200 Summit?

How might investor sentiment following this meet influence RPG Life Sciences' stock valuation in the immediate quarter?

Are there indications that RPG Life Sciences is preparing for any major corporate actions, such as M&A or new product launches, based on the timing of this disclosure?

RPG Life Sciences completes slump sale of APIs business to Raghava

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • RPG Life Sciences completes slump sale of APIs and intermediates business
  • Buyer is Raghava Life Sciences Private Limited
  • Transaction executed via subsidiary RPG Active Pharma Limited
  • Transfer effective from September 16, 2026
powered bylight_fuzz_icon
51049604

*this image is generated using AI for illustrative purposes only.

RPG Life Sciences has completed the slump sale of its Active Pharmaceutical Ingredients (APIs) and intermediates business to Raghava Life Sciences Private Limited. The transfer is effective from September 16, 2026.

The transaction was executed through a Business Transfer Agreement (BTA) between Raghava Life Sciences and RPG Active Pharma Limited, a wholly owned subsidiary of RPG Life Sciences. The deal involves the acquisition of the APIs and intermediates businesses as a going concern.

Transaction Details

RPG Life Sciences disclosed the completion to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company had previously informed the exchanges about the execution of the BTA on September 2, 2026.

Detail Information
Buyer Raghava Life Sciences Private Limited
Seller RPG Active Pharma Limited
Business Unit APIs and intermediates
Effective Date September 16, 2026
Transaction Type Slump sale (going concern)

Historical Stock Returns for RPG Life Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-3.29%-7.22%-2.98%+45.21%+19.92%+294.09%

How will RPG Life Sciences reallocate the capital from the API business sale to drive future growth in its core pharmaceutical segments?

What strategic advantages does Raghava Life Sciences gain by acquiring this API and intermediates unit as a going concern?

Will the slump sale impact RPG Life Sciences' current supply chain stability for its finished dosage forms in the short term?

More News on RPG Life Sciences

1 Year Returns:+19.92%